ClinicalTrials.gg
TerminatedNCT01117987IMPRES ExtnUpdated Aug 13, 2015Results posted

Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)

A Phase 3 interventional study of Imatinib and Placebo in Pulmonary Arterial Hypertension, sponsored by Novartis Pharmaceuticals. Terminated at 59 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-08-13.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Why this study was terminated
Novartis discontinued the development of imatinib in PAH due to requirement of regulatory authorities for additional data to secure marketing approval in PAH.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
144
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Pulmonary Arterial Hypertension by Novartis — 1 open to participants now, 1 under way, none of them phase 3. Pulmonary Arterial Hypertension · Novartis.

Enrollment
3rd of 12
144 · median 27
Started
2010
with 1 other
Phase 3
5 of 12
none open now
Registered
3rd of 12
by date

Among the 12 studies in Pulmonary Arterial Hypertension by Novartis, this one is the 3rd largest by enrollment, is one of 2 that started in 2010, is one of 5 in phase 3, and was the 3rd registered.

Pulmonary Arterial Hypertension

700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.

Browse Pulmonary Arterial Hypertension studies →

Open to participants now

1 of the 12 studies in Pulmonary Arterial Hypertension by Novartis is open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Pulmonary Arterial Hypertension by Novartis, or all of them as a file.
02

Study summary

This is a multinational, multi center extension study. This study will provide data on the long-term safety, tolerability, and efficacy of imatinib in the treatment of severe pulmonary arterial hypertension.

03

Conditions studied

  • Pulmonary Arterial Hypertension

Keywords

  • Pulmonary arterial hypertension, imatinib, 6MWD, pulmonary hypertension
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who participated in CQTI571A2301 clinical trial and completed the week 24 visit of the study protocol, including all Study Completion assessments
  • Patients who withdrew from the CQTI571A2301 study prematurely for reasons not related to study drug or not related to a safety issue but performed all Study Completion assessments

Exclusion criteria

Exclusion Criteria:

  • Patients with a pulmonary capillary wedge pressure > 15 mmHg at time of Study Completion assessments in core protocol CQTI571A2301. If pulmonary capillary wedge pressure is not attainable, then a left atrial pressure measurement may be used in its place.
  • \< 45%
  • Patients with thrombocytopenia, count \< 50E9/L (50E3/µL)
  • Patients with uncontrolled systemic arterial hypertension, systolic > 160 mmHg or diastolic > 90 mmHg
  • Patients with a > 450 ms for males and > 470 ms for females in the absence of right branch bundle block (based on Visit 1 if required to be performed)

Other protocol-defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
144 participants (actual)

Study arms

  • Experimental
    Core imatinib

    Depending on the participants' randomized treatment in the core study, CQTI571A2301 (NCT00902174), and their completion status in the core study, participants received imatinib at 200 mg qd, 400 mg qd, or 200 mg qd with an increase to 400 mg qd after 2 weeks, if tolerated.

    Drug: Imatinib · Drug: Placebo

  • Experimental
    Core placebo

    Depending on the participants' randomized treatment in the core study, CQTI571A2301 (NCT00902174), and their completion status in the core study, participants received imatinib at 200 mg qd, 400 mg qd, or 200 mg qd with an increase to 400 mg qd after 2 weeks, if tolerated.

    Drug: Imatinib · Drug: Placebo

Interventions

  • Participants, who received imatinib 200 mg in the core study, CQTI571A2301 (NCT00902174), and completed the core study, received imatinib 200 mg every day (qd) in the extension. Participants, who were randomized to receive imatinib 400 mg in the core study and completed the core study, received imatinib 400 mg qd in the extension. Participants, who terminated early from the core study or who were randomized to placebo and completed the core study, started the extension with imatinib 200 mg qd. After 2 weeks, the dose was increased to 400 mg qd if tolerated.

  • DrugPlacebo

    To preserve the blind of the core study until the core study, CQTI571A2301 (NCT00902174), was completed, participants received a blinded study drug package containing a 70-tablet bottle of imatinib and a 70-tablet bottle of matching placebo.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events, Serious Adverse Events and Deaths

    Adverse event monitoring was conducted throughout the study.

    Time frame: 204 weeks

Secondary outcomes

  1. Change From Core Study Baseline in Six-Minute Walk Distance (6MWD)

    A six minute walk test (6MWT) was performed in accordance with the guidleines of the American Thoracic Society (2002).

    Time frame: core study baseline, extension baseline, 12 weeks, 24 weeks, 48 weeks, 72 weeks, 96 weeks, 120 weeks, 144 weeks, 156 weeks, 204 weeks

  2. Percentage of Participants With Incidence of Clinical Worsening Events

    Clinical worsening events included death, overnight hospitalization for worsening of PAH, worsening of World Health Organization (WHO) functional class by at least one level (drop in WHO ), 15% decrease in the 6MWD as compared to baseline confirmed by two 6MWTs at two consecutive study visits (6MWD reduction), and drop in WHO \& 6MWD reduction. Some participants have fulfilled more than one criterion. Therefore, the sum of individual components may be higher than the total number of participants with clinical worsening.

    Time frame: 204 weeks

07

Results

Posted May 21, 2015
Limitations and caveats
Within primary outcome measure (OM) #1, an additional death (\>30 days post study completion) was included in the imatinib arm. The participant flow and secondary OM #2 reflect deaths that occurred up to and including 30 days post study completion.

Participant flow

Participant flow — Overall Study
MilestoneCore ImatinibCore Placebo
Started6678
Completed54
Not completed6174
Withdrew: Protocol deviation01
Withdrew: Subject no longer requires study drug10
Withdrew: Lost to follow-up11
Withdrew: Abnormal test procedure result20
Withdrew: Lack of efficacy34
Withdrew: Death510
Withdrew: Withdrawal by subject510
Withdrew: Adverse event1926
Withdrew: Administrative problems2522

Outcome measures

PrimaryNumber of Participants With Adverse Events, Serious Adverse Events and Deaths

Adverse event monitoring was conducted throughout the study.

Time frame:
204 weeks
Reported as:
Number · Participants
Number of Participants With Adverse Events, Serious Adverse Events and Deaths
ParticipantsCore ImatinibCore Placebo
Adverse events (non-serious and serious)6276
Serious adverse events4053
Deaths610
SecondaryChange From Core Study Baseline in Six-Minute Walk Distance (6MWD)

A six minute walk test (6MWT) was performed in accordance with the guidleines of the American Thoracic Society (2002).

Time frame:
core study baseline, extension baseline, 12 weeks, 24 weeks, 48 weeks, 72 weeks, 96 weeks, 120 weeks, 144 weeks, 156 weeks, 204 weeks
Reported as:
Mean · meters
Change From Core Study Baseline in Six-Minute Walk Distance (6MWD)
metersCore ImatinibCore Placebo
Extension baseline (n=61,77)42.98 ± 55.2094.91 ± 62.629
Week 12 (n=58,57)48.75 ± 60.88716.25 ± 64.992
Week 24 (n=54,53)44.71 ± 45.50619.34 ± 71.675
Week 48 (n=47,42)45.81 ± 72.15029.18 ± 65.198
Week 72 (n=40,39)49.54 ± 76.01956.46 ± 111.130
Week 96 (n=38,35)66.64 ± 71.08041.03 ± 54.495
Week 120 (n=32,29)83.19 ± 67.85537.43 ± 60.087
Week 144 (n=27,21)67.70 ± 64.00039.45 ± 79.356
Week 156 (n=21,18)72.60 ± 67.97230.17 ± 66.856
Week 204 (n=4,3)96.88 ± 42.0484.50 ± 25.608
SecondaryPercentage of Participants With Incidence of Clinical Worsening Events

Clinical worsening events included death, overnight hospitalization for worsening of PAH, worsening of World Health Organization (WHO) functional class by at least one level (drop in WHO ), 15% decrease in the 6MWD as compared to baseline confirmed by two 6MWTs at two consecutive study visits (6MWD reduction), and drop in WHO \& 6MWD reduction. Some participants have fulfilled more than one criterion. Therefore, the sum of individual components may be higher than the total number of participants with clinical worsening.

Time frame:
204 weeks
Reported as:
Number · Percentage of participants
Percentage of Participants With Incidence of Clinical Worsening Events
Percentage of participantsCore ImatinibCore Placebo
Total participants with clinical worsening50.046.2
Death (all deaths)7.612.8
Hospitalization for worsening of PAH33.328.2
Drop in WHO24.219.2
6MWD reduction12.119.2
Drop in WHO and 6MWD reduction1.53.8

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Core Imatinib—40/66 (60.6%)55/66 (83.3%)
Core Placebo—53/78 (67.9%)72/78 (92.3%)
Most frequent serious events
Showing 10 of 159
Most frequent serious events
EventCore ImatinibCore Placebo
Right ventricular failureCardiac disorders5/668/78
Pulmonary arterial hypertensionRespiratory, thoracic and mediastinal disorders6/668/78
SyncopeNervous system disorders2/667/78
Device related infectionInfections and infestations5/663/78
DyspnoeaRespiratory, thoracic and mediastinal disorders4/665/78
AnaemiaBlood and lymphatic system disorders3/662/78
PneumoniaInfections and infestations3/663/78
HaemoptysisRespiratory, thoracic and mediastinal disorders3/661/78
Respiratory failureRespiratory, thoracic and mediastinal disorders3/662/78
LeukopeniaBlood and lymphatic system disorders0/663/78
Most frequent other events
Showing 10 of 67
Most frequent other events
EventCore ImatinibCore Placebo
NauseaGastrointestinal disorders21/6639/78
Oedema peripheralGeneral disorders21/6632/78
DiarrhoeaGastrointestinal disorders18/6627/78
VomitingGastrointestinal disorders14/6625/78
NasopharyngitisInfections and infestations17/6624/78
HeadacheNervous system disorders12/6624/78
Periorbital oedemaEye disorders11/6623/78
CoughRespiratory, thoracic and mediastinal disorders16/6611/78
RashSkin and subcutaneous tissue disorders7/6613/78
ArthralgiaMusculoskeletal and connective tissue disorders5/6612/78

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Core ImatinibCore PlaceboTotal
Mean49.3 ± 15.5245.7 ± 13.3147.4 ± 14.42
Sex: Female, Male
Sex: Female, Male(Participants)Core ImatinibCore PlaceboTotal
Female5763120
Male91524
08

Study locations

59 sites
  • Novartis Investigative Site
    Birmingham, Alabama 35294-0006, United States
  • Novartis Investigative Site
    Phoenix, Arizona 85013, United States
  • Novartis Investigative Site
    Los Angeles, California 90095, United States
  • Novartis Investigative Site
    San Francisco, California 94143, United States
  • Novartis Investigative Site
    Weston, Florida 33331, United States
  • Novartis Investigative Site
    Chicago, Illinois 60637, United States
  • Novartis Investigative Site
    Rochester, Minnesota 55905, United States
  • Novartis Investigative Site
    St. Louis, Missouri 63110, United States
  • Novartis Investigative Site
    Omaha, Nebraska 68131, United States
  • Novartis Investigative Site
    Mineola, New York 11501, United States
  • Novartis Investigative Site
    New York, New York 10029, United States
  • Novartis Investigative Site
    Durham, North Carolina 27710, United States
  • Novartis Investigative Site
    Cincinnati, Ohio 45219, United States
  • Novartis Investigative Site
    Cleveland, Ohio 44195, United States
  • Novartis Investigative Site
    Oklahoma City, Oklahoma 73104, United States
  • Novartis Investigative Site
    Tualatin, Oregon 97062, United States
  • Novartis Investigative Site
    Pittsburgh, Pennsylvania 15213, United States
  • Novartis Investigative Site
    Houston, Texas 77030, United States
  • Novartis Investigative Site
    Milwaulkee, Wisconsin 53215, United States
  • Novartis Investigative Site
    Wien, A-1090, Austria
  • Novartis Investigative Site
    Leuven, 3000, Belgium
  • Novartis Investigative Site
    Calgary, Alberta T1Y 6J4, Canada
  • Novartis Investigative Site
    Edmonton, Alberta T6G 2B7, Canada
  • Novartis Investigative Site
    London, Ontario N6A 4G5, Canada
  • Novartis Investigative Site
    Clamart Cedex, 92141, France
  • Novartis Investigative Site
    Berlin, 12552, Germany
  • Novartis Investigative Site
    Berlin, 12683, Germany
  • Novartis Investigative Site
    Dresden, 01307, Germany
  • Novartis Investigative Site
    Hamburg, 20246, Germany
  • Novartis Investigative Site
    Hannover, 30625, Germany
  • Novartis Investigative Site
    Heidelberg, 69120, Germany
  • Novartis Investigative Site
    Homburg, 66421, Germany
  • Novartis Investigative Site
    Köln, 50937, Germany
  • Novartis Investigative Site
    Marburg, 35039, Germany
  • Novartis Investigative Site
    Muenchen, 81377, Germany
  • Novartis Investigative Site
    Regensburg, 93053, Germany
  • Novartis Investigative Site
    Würzburg, 97080, Germany
  • Novartis Investigative Site
    Pavia, (pv) 27100, Italy
  • Novartis Investigative Site
    Roma, RM 00161, Italy
  • Novartis Investigative Site
    Sendai-city, Miyagi 980-8574, Japan
  • Novartis Investigative Site
    Okayama-city, Okayama 701-1192, Japan
  • Novartis Investigative Site
    Hamamatsu, Shizuoka 431-3192, Japan
  • Novartis Investigative Site
    Bunkyo-ku, Tokyo 113-8655, Japan
  • Novartis Investigative Site
    Mitaka-city, Tokyo 181-8611, Japan
  • Novartis Investigative Site
    Seoul, Korea 110 744, Korea, Republic of
  • Novartis Investigative Site
    Seoul, Korea 120-752, Korea, Republic of
  • Novartis Investigative Site
    Seoul, Korea 135-710, Korea, Republic of
  • Novartis Investigative Site
    Amsterdam, 1081 HV, Netherlands
  • Novartis Investigative Site
    Malaga, Andalucia 29010, Spain
  • Novartis Investigative Site
    Sevilla, Andalucia 41013, Spain
  • Novartis Investigative Site
    Santander, Cantabria 39008, Spain
  • Novartis Investigative Site
    Barcelona, Catalunya 08035, Spain
  • Novartis Investigative Site
    Barcelona, Catalunya 08036, Spain
  • Novartis Investigative Site
    Madrid, 28041, Spain
  • Novartis Investigative Site
    St. Gallen, 9007, Switzerland
  • Novartis Investigative Site
    Cambridge, Cambridgeshire CB23 3RE, United Kingdom
  • Novartis Investigative Site
    Newcastle Upon Tyne, Newcastle NE7 7DN, United Kingdom
  • Novartis Investigative Site
    Sheffield, South Yorkshire S10 2JF, United Kingdom
  • Novartis Investigative Site
    London, NW3 3QG, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2010, a primary completion of Apr 2014 and a completion of Apr 2014. It does not say whether these dates are actual or estimated.

Results were first posted in May 2015, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 3, 2010
First posted
May 6, 2010
Start
Apr 2010
Primary completionActual
Apr 2014
CompletionActual
Apr 2014
Results first posted
May 21, 2015
Last update
Aug 13, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 13, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01117987
Responsible party
Sponsor
First posted
May 6, 2010
Start date
Apr 2010
Primary completion
Apr 2014
Completion
Apr 2014
Results posted
May 21, 2015
Last update
Aug 13, 2015

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Imatinib

Start the discussion